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Learning Objectives
1.

To review the incidence of cervical cancer in the United States and the
relationship between the HPV virus and invasive cervical cancer.

2.

To review the 2019 ASCCP guidelines and how they differ from 2012
guidelines.

3.

To discuss use of technology to aid in appropriate decision making and
management.

Cervical Cancer
Background

Cervical Cancer in the United States2

HPV and Cervical Cancer
High-risk HPV types are detected in >99% of cervical cancers.4
HPV16 and HPV18 are implicated in >70% of cervical cancers.3

HPV Vaccination
June 2006: Quadrivalent (6, 11, 16, 18) HPV
vaccine approved. Gardasil, Merck.
October 2009: Bivalent (16, 18) HPV vaccine
approved. Cervarix, GlaxoSmithKline.

While vaccination against HPV in the United
States is not as common as vaccination against
other conditions, the projection is that rates of
CIN3+ and cervical cancer will continue to
decrease as our vaccinated cohort ages.

December 2014: 9-valent ( 6, 11, 16, 18, 31, 33,
45, 52, 58) HPV vaccine approved. Gardasil-9,
Merck.

Quadrivalent HPV vaccine has been associated
with a substantially decreased risk of invasive
cervical cancer at a population level.5

Cervical Intraepithelial Neoplasia Progression

2012 ASCCP Consensus Guidelines6
●

First cervical cancer screening guidelines to be based on the principle,
“Equal management for equal risk.”

●

However, 2012 guidelines still relied to some degree on complicated,
result-based algorithms.

●

“The key difference between 2019 guidelines and previous versions is the
change from primarily test-results based algorithms to primarily risk-based
guidelines.”

2019 ASCCP Guidelines

Essential Change
#1
Recommendations are based on risk, not results.

7

Case #1
Patient A.A. is a 31y/o F who is seeing you as a new patient for an annual visit.
She recently moved to Philadelphia from Georgia and does not have any of her
previous records with her. She says that it has been at least 5 years since her last
pap smear and does not remember if she has had any abnormal results in the
past.
You perform co-testing in the oﬃce and the results are: HPV+, ASCUS.
What do you tell this patient for follow-up?

TABLE 1A: Immediate and 5-Year Risks of CIN 3+ for Abnormal
Screening Results, When There Are No Known Prior HPV Test Results1

Yes - 4.4%

7

Colposcopy
Results:
CIN1

What do you tell this patient for
follow up?

Table 3: CIN 3+ 1-Year and 5-Year Risks Upon Receipt of
Colposcopy/Biopsy Results1

7

1 year follow up
results:
HPV+ ASCUS

What do you tell this patient for
follow up?

Table 4A: Immediate and 5-Year Risks of CIN 3+ Postcolposcopy at
Which CIN 2+ Was Not Found, After Referral for Low-Grade Results1

No - 3.1%
6%

7

Essential Change
#2
Repeat HPV testing or cotesting (rather than colposcopy) is recommended for patients
with minor screening abnormalities indicating HPV infection with a low underlying risk
of CIN3+.

2019 ASCCP Guidelines1

2012 ASCCP Guidelines6

Essential Change
#3
Guidance for expedited treatment (treatment without colposcopic biopsy) is expanded.

2019 ASCCP Guidelines7:
For non-pregnant patients age 25+

2012 ASCCP Guidelines6

●

Expedited treatment is preferred
when the immediate risk of CIN 3+ ≥
60%

●

Expedited treatment is acceptable
for those with immediate risk of
CIN3+ between 25% and 60%

●

Expedited treatment is preferred for
patients with HSIL cytology an a
concurrent +HPV16 genotype

Case #2
A 30y/o F presents to your oﬃce for routine cervical cancer screening. She has
no history of abnormal paps. Her results return: HPV+, NILM. How do you
counsel her regarding follow-up?

1

Case #2
She follows up with you in 1 year as you recommend. This time her results
return: HPV+, HSIL. How do you counsel her?

1

Essential Change
#4
Excisional treatment is preferred over ablative treatment for histologic HSIL.
Adenocarcinoma in situ should be removed via excision.

Essential Change
#5
Observation is preferred to treatment for CIN1.

2012 ASCCP Guidelines6

2019 ASCCP Guidelines1

Essential Change
#6
Addresses the use of primary HPV testing!

“When primary HPV screening is used, performance of an additional reﬂex triage test
(e.g. reﬂex cytology) for all positive HPV tests regardless of genotype is preferred.”
“Use of primary HPV screening will likely increase in the future, as it is more effective
than screening with cytology alone and performs similarly to and with lower costs than
screening with co-testing.” 7

Who is eligible for primary HPV testing?
2015 Interim Clinical Guidance from ASCCP, ACS, ASCP8:
Primary hrHPV screening should not be initiated before 25 years of age.

2020 ACS Recommendations9:
The ACS recommends the primary HPV test as the preferred test for cervical
cancer screening for people 25-65 years of age.

Essential Change
#7
Addresses surveillance with HPV testing or co-testing after treatment of histologic
HSIL, CIN2, CIN3 or AIS.

Continued surveillance with HPV testing
or co-testing at 3 year intervals for at
least 25 years is recommended after
treatment and initial post-treatment
management of histologic HSIL, CIN2,
CIN3 or AIS.

2012 ASCCP Guidelines6

2019 ASCCP Guidelines7

There’s an app for that!

Case #3
A 28y/o F presents to your oﬃce to review the results of her colposcopy. She had
a prior pap smear with ASCUS, with reﬂex +HPV. Biopsies from her colposcopy
show CIN1. How do you counsel her?

ASCCP Management Guidelines App

ASCCP Management Guidelines

1

Recommendations for practice
●

It can be challenging for those of us in primary care to keep up with
relatively frequent changes to management guidelines, hence the
signiﬁcance of having up to date technology at our ﬁngertips. The use of
apps can aid PCPs in providing appropriate patient care.

●

EMR systems should contain a user-friendly interface for tracking cervical
cancer screening results and ensuring appropriate follow up.

Take home points - Top 3
1.

Recommendations for further management should now be based on patient
risk, not just test results.

2.

Primary HPV screening will likely be an important component of cervical
cancer screening in the future.

3.

Technology is your friend in keeping up to date with changing guidelines.
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